Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Oncogenic LncRNA CASC9 in Cancer Progression

Author(s): Yuying Qi, Chaoying Song, Jiali Zhang, Chong Guo* and Chengfu Yuan*

Volume 27, Issue 4, 2021

Published on: 17 September, 2020

Page: [575 - 582] Pages: 8

DOI: 10.2174/1381612826666200917150130

Price: $65

Abstract

Background: Long non-coding RNAs (LncRNAs), with the length of over 200 nucleotides, that originate from intergenic, antisense, or promoter-proximal regions, are a large family of RNAs that lack coding capacity. Emerging evidences illustrated that LncRNAs played significant roles in a variety of cellular functions and biological processes in profuse human diseases, especially in cancers. Cancer susceptibility candidate 9 (CASC9), as a member of the LncRNAs group, firstly found its oncogenic function in esophageal cancer. In the following recent studies, a growing amount of human malignancies are verified to be correlated with CASC9, most of which are derived from the squamous epithelium tissue. This present review attempts to highlight the latest insights into the expression, functional roles, and molecular mechanisms of CASC9 in different human malignancies.

Methods: In this review, the latest findings related to the pathophysiological processes of CASC9 in human cancers were summarized and analyzed, and the associated studies collected in systematic retrieval of PubMed used lncRNA and CASA9 as keywords.

Results: CASC9 expression is identified to be aberrantly elevated in a variety of malignancies. The over-expression of CASC9 has been suggested to accelerate cell proliferation, migration, cell growth and drug resistance of cancer cells, while depressing cell apoptosis, revealing its role as an oncogene. Moreover, the current review demonstrated CASC9 as closely related to the neoplastic transformation of squamous epithelial cells and squamous metaplasia in non-squamous epithelial tissues. Finally, we discuss the limitations and tremendous diagnostic/ therapeutic potential of CASC9 in various human cancers.

Conclusion: Long non-coding RNA CASC9 likely serve as useful disease biomarkers or therapeutic targets which be effectively applied in the treatment of different kinds of cancers.

Keywords: LncRNAs, cancer susceptibility candidate 9 (CASC9), cancers, biomarkers, intergenic, antisense, promoter-proximal regions.

« Previous
[1]
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69(5): 363-85.
[http://dx.doi.org/10.3322/caac.21565] [PMID: 31184787]
[2]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144(8): 1941-53.
[http://dx.doi.org/10.1002/ijc.31937] [PMID: 30350310]
[3]
Weidle UH, Birzele F, Kollmorgen G, Rüger R. Long non-coding RNAs and their role in metastasis. Cancer Genomics Proteomics 2017; 14(3): 143-60.
[http://dx.doi.org/10.21873/cgp.20027] [PMID: 28446530]
[4]
Guo C, et al. Pathophysiological Functions of the lncRNA TUG1. Curr Pharm Des 2020; 26(6): 688-700.
[PMID: 31880241]
[5]
Pan Z, Mao W, Bao Y, Zhang M, Su X, Xu X. The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer. Cancer Med 2016; 5(9): 2442-7.
[http://dx.doi.org/10.1002/cam4.770] [PMID: 27431358]
[6]
Shao G, Wang M, Fan X, et al. lncRNA CASC9 positively regulates CHK1 to promote breast cancer cell proliferation and survival through sponging the miR‑195/497 cluster. Int J Oncol 2019; 54(5): 1665-75.
[http://dx.doi.org/10.3892/ijo.2019.4734] [PMID: 30816435]
[7]
Yang Y, Chen D, Liu H, Yang K. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis 2019; 10(2): 41.
[http://dx.doi.org/10.1038/s41419-018-1280-8] [PMID: 30674868]
[8]
Shang C, Sun L, Zhang J, et al. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget 2017; 8(9): 15393-8.
[http://dx.doi.org/10.18632/oncotarget.14871] [PMID: 28146436]
[9]
Su X, Li G, Liu W. The Long Noncoding RNA Cancer susceptibility candidate 9 promotes nasopharyngeal carcinogenesis via stabilizing HIF1α. DNA Cell Biol 2017; 36(5): 394-400.
[http://dx.doi.org/10.1089/dna.2016.3615] [PMID: 28398871]
[10]
Schwartz L, Supuran CT, Alfarouk KO. The warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem 2017; 17(2): 164-70.
[http://dx.doi.org/10.2174/1871520616666161031143301] [PMID: 27804847]
[11]
Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol 2019; 21(4): 498-510.
[http://dx.doi.org/10.1038/s41556-019-0299-0] [PMID: 30936474]
[12]
Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505(7483): 344-52.
[http://dx.doi.org/10.1038/nature12986] [PMID: 24429633]
[13]
Wu Y, Hu L, Liang Y, et al. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer 2017; 16(1): 150.
[http://dx.doi.org/10.1186/s12943-017-0715-7] [PMID: 28854977]
[14]
Liang Y, Chen X, Wu Y, et al. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ 2018; 25(11): 1980-95.
[http://dx.doi.org/10.1038/s41418-018-0084-9] [PMID: 29511340]
[15]
Ma P, et al. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 87: 20-6.
[http://dx.doi.org/10.1016/j.biopha.2016.12.079]
[16]
Luo K, et al. LncRNA CASC9 interacts with CPSF3 to regulate TGF-β signaling in colorectal cancer. Journal of experimental & clinical cancer research CR (East Lansing Mich) 2019; 38: 249.
[17]
Ganguly D, Fan M, Yang CH, et al. The critical role that STAT3 plays in glioma-initiating cells: STAT3 addiction in glioma. Oncotarget 2018; 9(31): 22095-112.
[http://dx.doi.org/10.18632/oncotarget.25188] [PMID: 29774125]
[18]
Chamcheu JC, Roy T, Uddin MB, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: A review of current status and future trends on natural and synthetic agents therapy. Cells 2019; 8(8): 8.
[http://dx.doi.org/10.3390/cells8080803] [PMID: 31370278]
[19]
Chen M, Xu X, Ma H. Identification of oncogenic long noncoding RNAs CASC9 and LINC00152 in oral carcinoma through genome-wide comprehensive analysis. Anticancer Drugs 2019; 30(4): 356-62.
[http://dx.doi.org/10.1097/CAD.0000000000000725] [PMID: 30543527]
[20]
Yu X, Lin Y, Sui W, Zou Y, Lv Z. Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. Cancer Med 2017; 6(3): 673-80.
[http://dx.doi.org/10.1002/cam4.1027] [PMID: 28220683]
[21]
Noh JH, Gorospe M. AKTions by Cytoplasmic lncRNA CASC9 promote hepatocellular carcinoma survival. Hepatology 2018; 68(5): 1675-7.
[http://dx.doi.org/10.1002/hep.30165] [PMID: 30014487]
[22]
Xi J, Wang Y, Liu H. GLUT-1 participates in the promotion of LncRNA CASC9 in proliferation and metastasis of laryngeal carcinoma cells. Gene 2020; 726: 144194.
[http://dx.doi.org/10.1016/j.gene.2019.144194] [PMID: 31669650]
[23]
Jin Y, Xie H, Duan L, Zhao D, Ding J, Jiang G. Long Non-Coding RNA CASC9 And HIF-1α form a positive feedback loop to facilitate cell proliferation and metastasis in lung cancer. OncoTargets Ther 2019; 12: 9017-27.
[http://dx.doi.org/10.2147/OTT.S226078] [PMID: 31802910]
[24]
Zhang J, Wang Q, Quan Z. Long non-coding RNA CASC9 enhances breast cancer progression by promoting metastasis through the meditation of miR-215/TWIST2 signaling associated with TGF-β expression. Biochem Biophys Res Commun 2019; 515(4): 644-50.
[http://dx.doi.org/10.1016/j.bbrc.2019.05.080] [PMID: 31178137]
[25]
Hu X, Li Y, Kong D, Hu L, Liu D, Wu J. Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer. J Cell Physiol 2019; 234(7): 10800-8.
[http://dx.doi.org/10.1002/jcp.27903] [PMID: 30537154]
[26]
Li X, Chen B, Chi D, Zhang Y, Jiang W. lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1. OncoTargets Ther 2019; 12: 423-32.
[http://dx.doi.org/10.2147/OTT.S181914] [PMID: 30662268]
[27]
Liu H, Li C, Yang J, et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis. J Cell Mol Med 2018; 22(12): 6338-44.
[http://dx.doi.org/10.1111/jcmm.13932] [PMID: 30270508]
[28]
Chen Y, Li Y, Gao H. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p. Cancer Med 2020; 9(5): 1830-41.
[http://dx.doi.org/10.1002/cam4.2839] [PMID: 31943867]
[29]
Lala M, Chirovsky D, Cheng JD, Mayawala K. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. Oral Oncol 2018; 84: 108-20.
[http://dx.doi.org/10.1016/j.oraloncology.2018.07.005] [PMID: 30115469]
[30]
Chen X, Xu H, Sun G, Zhang Y. LncRNA CASC9 affects cell proliferation, migration, and invasion of tongue squamous cell carcinoma via Regulating miR-423-5p/SOX12 Axes. Cancer Manag Res 2020; 12: 277-87.
[http://dx.doi.org/10.2147/CMAR.S220351] [PMID: 32021442]
[31]
Fang J, Chen W, Meng XL. LncRNA CASC9 suppressed the apoptosis of gastric cancer cells through regulating BMI1. Pathol Oncol Res 2020; 26(1): 475-82.
[http://dx.doi.org/10.1007/s12253-019-00703-3] [PMID: 31642035]
[32]
Alsahafi E, Begg K, Amelio I, et al. Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis 2019; 10(8): 540.
[http://dx.doi.org/10.1038/s41419-019-1769-9] [PMID: 31308358]
[33]
Klingenberg M, Groß M, Goyal A, et al. The Long Noncoding RNA cancer susceptibility 9 and RNA binding protein heterogeneous nuclear ribonucleoprotein L form a complex and coregulate genes linked to AKT signaling. Hepatology 2018; 68(5): 1817-32.
[http://dx.doi.org/10.1002/hep.30102] [PMID: 29790588]
[34]
Gramantieri L, Baglioni M, Fornari F, et al. LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget 2018; 9(80): 35085-99.
[http://dx.doi.org/10.18632/oncotarget.26202] [PMID: 30416681]
[35]
Liu L, Zhang Y, Wang J, Su H, Zhao Y. Long non-coding RNA CASC9 knockdown inhibits the progression of nasopharyngeal carcinoma by regulating miR-145. Int J Clin Exp Pathol 2019; 12(11): 4024-33.
[PMID: 31933798]
[36]
Gao L, Guo YN, Zeng JH, et al. The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation. Int J Oncol 2019; 54(5): 1651-64.
[http://dx.doi.org/10.3892/ijo.2019.4758] [PMID: 30896821]
[37]
Long L, Huang G, Zhu H, Guo Y, Liu Y, Huo J. Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med 2013; 11: 275.
[http://dx.doi.org/10.1186/1479-5876-11-275] [PMID: 24171926]
[38]
Wei WF, Zhou CF, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8(12): 3220.
[http://dx.doi.org/10.1038/s41419-017-0077-5] [PMID: 29242498]
[39]
Jiang B, Li Y, Qu X, et al. Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin‑resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med 2018; 42(5): 2801-10.
[http://dx.doi.org/10.3892/ijmm.2018.3812] [PMID: 30106089]
[40]
La Vecchia C. Ovarian cancer: Epidemiology and risk factors. European journal of cancer prevention : The official journal of the European Cancer Prevention Organisation (ECP) 2017; 26: 55-62.
[http://dx.doi.org/10.1097/CEJ.0000000000000217]
[41]
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68(4): 297-316.
[http://dx.doi.org/10.3322/caac.21446] [PMID: 29846940]
[42]
Fugazzola L, Muzza M, Pogliaghi G, Vitale M. Intratumoral genetic heterogeneity in papillary thyroid cancer: Occurrence and clinical significance. Cancers (Basel) 2020; 12(2): 12.
[http://dx.doi.org/10.3390/cancers12020383] [PMID: 32046148]

Rights & Permissions Print Cite
Article Metrics
47
4
© 2024 Bentham Science Publishers | Privacy Policy